Survival implications of opioid use before and after liver transplantation

Henry B. Randall, Tarek Alhamad, Mark A. Schnitzler, Zidong Zhang, Sophia Ford‐Glanton, David A. Axelrod, Dorry L. Segev, Bertram L. Kasiske, Gregory P. Hess, Hui Yuan, Rosemary Ouseph, Krista L. Lentine – 27 December 2016 – Implications of prescription opioid use for outcomes after liver transplantation (LT) have not been described. We integrated national transplant registry data with records from a large pharmaceutical claims clearinghouse (2008‐2014; n = 29,673).

Human macrophage ferroportin biology and the basis for the ferroportin disease

Manuela Sabelli, Giuliana Montosi, Cinzia Garuti, Angela Caleffi, Stefania Oliveto, Stefano Biffo, Antonello Pietrangelo – 27 December 2016 – Ferroportin (FPN1) is the sole iron exporter in mammals, but its cell‐specific function and regulation are still elusive. This study examined FPN1 expression in human macrophages, the cells that are primarily responsible on a daily basis for plasma iron turnover and are central in the pathogenesis of ferroportin disease (FD), the disease attributed to lack‐of‐function FPN1 mutations.

Reply

Deirdre Kelly, Steffen Hartleif, Henkjan J. Verkade, Jeremy Rajanayagam, Patrick McKiernan, George Mazariegos, Stefan Hübscher – 27 December 2016

Outcomes of liver retransplantation in patients with primary sclerosing cholangitis

Jacqueline B. Henson, Yuval A. Patel, Lindsay Y. King, Jiayin Zheng, Shein‐Chung Chow, Andrew J. Muir – 27 December 2016 – Liver retransplantation in patients with primary sclerosing cholangitis (PSC) has not been well studied. The aims of this study were to characterize patients with PSC listed for and undergoing retransplantation and to describe the outcomes in these patients.

Long noncoding RNA HULC modulates the phosphorylation of YB‐1 through serving as a scaffold of extracellular signal–regulated kinase and YB‐1 to enhance hepatocarcinogenesis

Dan Li, Xuefeng Liu, Jian Zhou, Jie Hu, Dongdong Zhang, Jing Liu, Yanyan Qiao, Qimin Zhan – 27 December 2016 – Dysregulated expression of long noncoding RNAs has been reported in many types of cancers, indicating that it may play a critical role in tumorigenesis. The long noncoding RNA highly up‐regulated in liver cancer (HULC) was first characterized in hepatocellular carcinoma. However, the detailed mechanisms of HULC remain unclear.

Subscribe to